Last reviewed 2026-04-23 · How we verify

Tislelizumab+Oxaliplatin+Capecitabine

Tislelizumab+Oxaliplatin+Capecitabine is a PD-1 inhibitor + chemotherapy combination Small molecule drug developed by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. It is currently in Phase 3 development for Gastric or gastroesophageal junction cancer (Phase 3 development).

This combination uses a PD-1 inhibitor to enhance immune response against cancer cells while chemotherapy agents directly kill rapidly dividing cells.

This combination uses a PD-1 inhibitor to enhance immune response against cancer cells while chemotherapy agents directly kill rapidly dividing cells. Used for Gastric or gastroesophageal junction cancer (Phase 3 development).

At a glance

Mechanism of action

Tislelizumab is a humanized PD-1 inhibitor that blocks the PD-1/PD-L1 checkpoint, allowing T cells to recognize and attack cancer cells. Oxaliplatin and capecitabine are chemotherapy agents that work synergistically—oxaliplatin is a platinum-based agent causing DNA damage, while capecitabine is a fluoropyrimidine prodrug that inhibits thymidylate synthase. The combination leverages immunotherapy with conventional chemotherapy for enhanced anti-tumor activity.

Approved indications

• Gastric or gastroesophageal junction cancer (Phase 3 development)

Common side effects

• Neutropenia
• Anemia
• Thrombocytopenia
• Nausea and vomiting
• Diarrhea
• Hand-foot skin reaction
• Immune-related adverse events (fatigue, rash)

Key clinical trials

• A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (PHASE3)
• A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (PHASE3)
• Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer (PHASE2)
• Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01） (PHASE2)
• Perioperative Chemotherapy With Low-Dose Radiotherapy and Tislelizumab for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (PHASE2)
• A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04] (PHASE2)
• Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma. (PHASE3)
• ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Tislelizumab+Oxaliplatin+Capecitabine CI brief — competitive landscape report
• Tislelizumab+Oxaliplatin+Capecitabine updates RSS · CI watch RSS
• Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. portfolio CI

Frequently asked questions about Tislelizumab+Oxaliplatin+Capecitabine

Related

• Drug class: All PD-1 inhibitor + chemotherapy combination drugs
• Target: All drugs targeting PD-1 (programmed death receptor 1); DNA (oxaliplatin); thymidylate synthase (capecitabine)
• Manufacturer: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. — full pipeline
• Therapeutic area: All drugs in Oncology
• Indication: Drugs for Gastric or gastroesophageal junction cancer (Phase 3 development)
• Compare: Tislelizumab+Oxaliplatin+Capecitabine vs similar drugs
• Pricing: Tislelizumab+Oxaliplatin+Capecitabine cost, discount & access